Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta- thalassemia Major in Iran; A Non-randomized Controlled Trial
Journal Title: Iranian Journal of Blood and Cancer - Year 2016, Vol 8, Issue 4
Abstract
Background: Iron chelators are an important part of management of patients with thalassemia. It is prudent to compare efficacy of different iron chelators in treatment of iron overload in these patients who receive regular blood transfusion. We aimed to compare the efficacy and safety of available oral iron chelator; Deferasirox (Exjade®) with Deferasirox (Osveral®) in reducing iron overload in patients with β-thalassemia major. Methods: Children suffering from β-thalassemia major referring to Mofid Children Hospital were enrolled in this non-randomized clinical trial. The patients were divided into two groups receiving Deferasirox (Exjade®) versus Deferasirox (Osveral®) and their response to either treatment was assessed by measurement of serum ferritin levels and estimation of cardiac and liver iron by MRI T2* of heart and liver. Efficacy of either medication was compared before and after 12 months of treatment. Serum ferritin levels were measured every three months. Mean serum ferritin at baseline was compared with post-treatment values. MRI T2* of heart and liver was performed before and after treatment. Results: Out of 69 patients with a mean age of 13.6±7.4 years, 42 (60.9%) were male. 30 patients were assigned to take Deferasirox (Exjade®) and 39 patients to take Deferasirox (Osveral®). The groups were not different regarding the age and the gender (P=0.18 and 0.621, respectively). There was no statistically significant difference in post-treatment serum ferritin level measurements between the two groups. In patients who received Osveral®, decrease in liver iron overload was significant (0.99 ms in Exjade® group vs 1.16 ms in Osveral® group, p=0.007). In the group of patients who received Exjade®, decrease in cardiac iron overload was significant (4.52 in Exjade group vs. 1.71 in Osveral group, P<0.001). Conclusion: Deferasirox (Osveral®), the iron chelator manufactured in Iran, was as efficient as Deferasirox (Exjade®) in iron removal and could be a substitute for Deferasirox (Exjade®).
Authors and Affiliations
Neda Ashayeri, Elham Sadeghi, Sara Sadeghi, Peyman Eshghi, Samin Alavi
Keywords
Related Articles
- EP ID EP248720
- DOI -
- Views 114
- Downloads 0
Evaluating the frequency of HTLV-Ι/Π infection among blood donors, major thalassemic patients and individuals infected with hepatitis B and C viruses in Isfahan, Iran
Background: The human T-cell lymphotropic virus type I is the first retrovirus idenfied in humans. The virus has been associated with adult T-cell leukemia/lymphoma, human T-lymphotropic virus type I, myelopathy/tropica...
University Students Awareness and Attitude towards Blood Donation in Kerman City
Background: Blood transfusion is one of the most crucial needs of the society in multiple diseases and injuries. The only source of blood is donation. Students consist a large and healthy group who are able of providing...
Prevalence of Delta Beta Thalassemia Minor in Southern Iran
Background: Hb A2 is elevated in subjects with beta thalassemia minor but small percent of carriers have normal Hb A2 with elevated levels of HbF (2-10%). This type of thalassemia is called delta beta thalassemia, and ca...
Detection Of 11q23 Gene Rearrangement In Children With Acute Lymphoblastic Leukemia And Its Association With Demographic Data and Response To Initial Chemotherapy On The Seventh Day Of Induction
Background: Acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer leading to cancer-related death in children. Most infants with ALL harbor recurring structural chromosomal rearrangements that ar...
Hyperimmunes Plasma Procurement and Products
This article has no abstract.